Abstract 5803: Discovery of a paralog selective p300 protein degrader with potent anti-cancer activity in hematological malignancies
Marwa Asem(University of Notre Dame), Jürgen Dinges(Abbott Fund), Daniel T. Cohen(AbbVie (United States)), Vlasios Manaves(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Yifei Kong(AbbVie (United States)), Milad Rouhimoghadam(University of Iowa), Anlu Chen(AbbVie (United States)), J.A. Ronau(AbbVie (United States)), Justin M. Reitsma(AbbVie (United States)), Shaun M. McLoughlin(AbbVie (United States)), Ryan A. McClure(AbbVie (United States)), Yu Shen, Stephanie Sandoval(AbbVie (United States)), Andrea G. Shergalis(AbbVie (United States)), Colin R. Woodford(AbbVie (United States)), Xiaohong Song(AbbVie (United States)), Sreenivas Punna(AbbVie (United States)), Alla Korepanova(AbbVie (United States)), Yan Zhai(AbbVie (United States)), Peter Kovar(AbbVie (United States))
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
|ACS Medicinal Chemistry Letters|2014|331